Revolution Medicines, Inc. RVMD
Revolution Medicines, Inc. (Nasdaq: RVMD) is an oncology drug developer. Its lead program, daraxonrasib, is in Phase 3 for Previously treated metastatic pancreatic ductal adenocarcinoma. Its next catalyst on record is elironrasib: Global Phase 3 RASolve 307 of elironrasib plus standard of care expected to start in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: elironrasib — Global Phase 3 RASolve 307 of elironrasib plus standard of care expected to start in Q4 2026. (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| daraxonrasib | 2L metastatic PDAC | small molecule | Phase 3 |
| zoldonrasib | KRAS G12D NSCLC/PDAC | small molecule | Phase 3 |
| elironrasib | KRAS G12C NSCLC | small molecule | Phase 3 |
| RMC-5127 | KRAS G12V | small molecule | Phase 1 |
| RMC-0708 | Undisclosed | small molecule | Pre-clinical |
| RMC-8839 | Undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- Aug 5, 2026positive Initial combination data in first-line RAS G12D NSCLC: 82% ORR (confirmed and pending confirmation) and 100% DCR (n=28 evaluable of 38), with minimal added toxicity.
the zoldonrasib plus standard of care combination demonstrated encouraging preliminary antitumor activity, including an overall response rate (ORR; confirmed and pending confirmation) of 82% and disease control rate (DCR) of 100%.
Filing - Aug 5, 2026positive Combination data in first-line RAS G12C NSCLC (n=39): 85% confirmed ORR, 97% DCR, 95% progression-free at 6 months.
the elironrasib plus standard of care combination demonstrated encouraging preliminary antitumor activity, including a confirmed ORR of 85% and DCR of 97%.
Filing - Aug 5, 2026met Phase 3 RASolute 302 met dual primary endpoints of overall survival and PFS versus chemotherapy (ASCO plenary and NEJM publication); no numbers given in this release.
The study demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival (PFS) as well as in patient-reported quality of life compared with chemotherapy, with a manageable safety profile.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.